543 related articles for article (PubMed ID: 26794729)
21. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
22. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Pond GR; Berry WR; Galsky MD; Wood BA; Leopold L; Sonpavde G
Clin Genitourin Cancer; 2012 Dec; 10(4):239-45. PubMed ID: 23000202
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
24. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.
Jin Y; An X; Cai YC; Cao Y; Cai XY; Xia Q; Tan YT; Jiang WQ; Shi YX
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1545-51. PubMed ID: 21842218
[TBL] [Abstract][Full Text] [Related]
30. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
33. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial.
Seider MJ; Pugh SL; Langer C; Wyatt G; Demas W; Rashtian A; Clausen CL; Derdel JD; Cleary SF; Peters CA; Ramalingam A; Clarkson JE; Tomblyn M; Rabinovitch RA; Kachnic LA; Berk LB;
Ann Nucl Med; 2018 Oct; 32(8):553-560. PubMed ID: 30094545
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Nayyar R; Sharma N; Gupta NP
Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Kattan J; Bachour M; Farhat F; El Rassy E; Assi T; Ghosn M
Invest New Drugs; 2016 Aug; 34(4):474-80. PubMed ID: 27159981
[TBL] [Abstract][Full Text] [Related]
37. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
[TBL] [Abstract][Full Text] [Related]
38. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
40. Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report.
Samelis GF; Ekmektzoglou KA; Tsiakou A; Giannakaki S; Georgoulias D; Christophilopoulos K
J BUON; 2011; 16(4):738-43. PubMed ID: 22331731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
